Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

DDX39 acts as a suppressor of invasion for bladder cancer.

Kato M, Wei M, Yamano S, Kakehashi A, Tamada S, Nakatani T, Wanibuchi H.

Cancer Sci. 2012 Jul;103(7):1363-9. doi: 10.1111/j.1349-7006.2012.02298.x. Epub 2012 Jun 4.

2.

An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.

Dickinson AJ, Fox SB, Newcomb PV, Persad RA, Sibley GN, Harris AL.

J Urol. 1995 Jul;154(1):237-41.

PMID:
7776437
3.

Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas.

Ohlsson G, Moreira JM, Gromov P, Sauter G, Celis JE.

Mol Cell Proteomics. 2005 Apr;4(4):570-81. Epub 2005 Feb 25.

4.

N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.

Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, Bittard H.

Clin Cancer Res. 2006 May 1;12(9):2780-7.

5.

Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.

Wild PJ, Herr A, Wissmann C, Stoehr R, Rosenthal A, Zaak D, Simon R, Knuechel R, Pilarsky C, Hartmann A.

Clin Cancer Res. 2005 Jun 15;11(12):4415-29.

6.

Expression analysis of VEGF-A and VEGF-B: relationship with clinicopathological parameters in bladder cancer.

Fauconnet S, Bernardini S, Lascombe I, Boiteux G, Clairotte A, Monnien F, Chabannes E, Bittard H.

Oncol Rep. 2009 Jun;21(6):1495-504.

PMID:
19424629
7.

Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.

Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A, Huland H.

Eur Urol. 2004 Jun;45(6):737-43.

PMID:
15149745
8.

Association of TSC1/hamartin, 14-3-3sigma, and p27 expression with tumor outcomes in patients with pTa/pT1 urothelial bladder carcinoma.

Mhawech-Fauceglia P, Alvarez V, Fischer G, Beck A, Herrmann FR.

Am J Clin Pathol. 2008 Jun;129(6):918-23. doi: 10.1309/D81QMXPMC3QHT57Y.

PMID:
18480009
9.

Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.

Tsui KH, Cheng AJ, Chang Pe, Pan TL, Yung BY.

Urology. 2004 Oct;64(4):839-44.

PMID:
15491744
10.

Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.

Kim EJ, Lee YS, Kim YJ, Kim MJ, Ha YS, Jeong P, Lee OJ, Kim WJ.

Urology. 2010 Jun;75(6):1516.e9-13. doi: 10.1016/j.urology.2009.08.055. Epub 2009 Nov 13.

PMID:
19913893
11.

Decreased expression of KAI1 metastasis suppressor gene is a recurrence predictor in primary pTa and pT1 urothelial bladder carcinoma.

Su JS, Arima K, Hasegawa M, Franco OE, Umeda Y, Yanagawa M, Sugimura Y, Kawamura J.

Int J Urol. 2004 Feb;11(2):74-82.

12.

RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.

Yan C, Kim YW, Ha YS, Kim IY, Kim YJ, Yun SJ, Moon SK, Bae SC, Kim WJ.

J Surg Oncol. 2012 Mar 15;105(4):425-30. doi: 10.1002/jso.22087. Epub 2011 Aug 30.

PMID:
22311819
13.

Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer.

Yamamoto Y, Matsuyama H, Furuya T, Oga A, Yoshihiro S, Okuda M, Kawauchi S, Sasaki K, Naito K.

Clin Cancer Res. 2004 Oct 1;10(19):6449-55.

14.

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.

Bodoor K, Ghabkari A, Jaradat Z, Alkhateeb A, Jaradat S, Al-Ghazo MA, Matalka I, Musleh H, Haddad Y.

Cancer Epidemiol. 2010 Dec;34(6):724-32. doi: 10.1016/j.canep.2010.05.003. Epub 2010 Jun 9.

PMID:
20542753
16.

Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer.

Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF Jr.

Clin Cancer Res. 2004 Jun 1;10(11):3800-6.

17.

Down-regulation of S100C is associated with bladder cancer progression and poor survival.

Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):606-11.

18.

Dual role of TGFBR3 in bladder cancer.

Liu XL, Xiao K, Xue B, Yang D, Lei Z, Shan Y, Zhang HT.

Oncol Rep. 2013 Sep;30(3):1301-8. doi: 10.3892/or.2013.2599. Epub 2013 Jul 8.

PMID:
23835618
19.

Fibulin-5 is down-regulated in urothelial carcinoma of bladder and inhibits growth and invasion of human bladder cancer cell line 5637.

Hu Z, Ai Q, Xu H, Ma X, Li HZ, Shi TP, Wang C, Gong DJ, Zhang X.

Urol Oncol. 2011 Jul-Aug;29(4):430-5. doi: 10.1016/j.urolonc.2009.06.004. Epub 2009 Sep 19.

PMID:
19767220
20.

Supplemental Content

Support Center